CEACAM1 regulates TIM-3-mediated tolerance and exhaustion
Open accessThe DOI matches its Crossref record; 58 of the 58 references it cites were found in a registry or an index.
Abstract
T-cell immunoglobulin domain and mucin domain-3 (TIM-3, also known as HAVCR2) is an activation-induced inhibitory molecule involved in tolerance and shown to induce T-cell exhaustion in chronic viral infection and cancers. Under some conditions, TIM-3 expression has also been shown to be stimulatory. Considering that TIM-3, like cytotoxic T lymphocyte antigen 4 (CTLA-4) and programmed death 1 (PD-1), is being targeted for cancer immunotherapy, it is important to identify the circumstances under which TIM-3 can inhibit and activate T-cell responses. Here we show that TIM-3 is co-expressed and forms a heterodimer with carcinoembryonic antigen cell adhesion molecule 1 (CEACAM1), another well-known molecule expressed on activated T cells and involved in T-cell inhibition. Biochemical, biophysical and X-ray crystallography studies show that the membrane-distal immunoglobulin-variable (IgV)-like amino-terminal domain of each is crucial to these interactions. The presence of CEACAM1 endows TIM-3 with inhibitory function. CEACAM1 facilitates the maturation and cell surface expression of TIM-3 by forming a heterodimeric interaction in cis through the highly related membrane-distal N-terminal domains of each molecule. CEACAM1 and TIM-3 also bind in trans through their N-terminal domains. Both cis and trans interactions between CEACAM1 and TIM-3 determine the tolerance-inducing function of TIM-3. In a mouse adoptive transfer colitis model, CEACAM1-deficient T cells are hyper-inflammatory with reduced cell surface expression of TIM-3 and regulatory cytokines, and this is restored by T-cell-specific CEACAM1 expression. During chronic viral infection and in a tumour environment, CEACAM1 and TIM-3 mark exhausted T cells. Co-blockade of CEACAM1 and TIM-3 leads to enhancement of anti-tumour immune responses with improved elimination of tumours in mouse colorectal cancer models. Thus, CEACAM1 serves as a heterophilic ligand for TIM-3 that is required for its ability to mediate T-cell inhibition, and this interaction has a crucial role in regulating autoimmunity and anti-tumour immunity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Interaction between TIM-3 and its four ligands (galectin 9, high mobility group protein B1, phosphatidyl serine, and carcinoembryonic antigen cell adhesion molecule 1) can diminish anti-tumor immunity through a variety of mechanisms including inducing CD8+ T cell death and exhaustion (Huang et al., 2015).”
From Hallmarks of response, resistance, and toxicity to immune checkpoint blockade (2021) · cites this paper as Huang et al., 2015
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“We stimulated primary microglia with galectin-9 and CEACAM1, both of which mediate TIM-3 function in T cells by phosphorylating Y256 and Y263 residues34,35. This treatment had no effect on pSMAD2 expression”
From Immune checkpoint TIM-3 regulates microglia and Alzheimer’s disease (2025) · cites this paper as [35]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Coot : model-building tools for molecular graphics
Emsley, P., & Cowtan, K. (2004) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444904019158 · Cited by 30,571 · cited 2×
“MolecularreplacementwasperformedwithMolrep,refinementswereperformedwithPHENIX 42 and intermittent model building was performed with COOT 43 , as described above.”
PHENIX : a comprehensive Python-based system for macromolecular structure solution
Adams, P. D., Afonine, P. V., Bunkóczi, G., Chen, V. B., Davis, I. W., Echols, N., Headd, J. J., Hung, L.-W., Kapral, G. J., Grosse-Kunstleve, R. W., et al. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444909052925 · Cited by 23,716 · cited 4×
“MolecularreplacementwasperformedwithMolrep,refinementswereperformedwithPHENIX 42 and intermittent model building was performed with COOT 43 , as described above.”
InfluentialHaploview: analysis and visualization of LD and haplotype maps
Barrett, J. C., Fry, B., Maller, J., & Daly, M. J. (2005) · Bioinformatics · doi:10.1093/bioinformatics/bth457 · Cited by 14,525
Overview of the CCP 4 suite and current developments
Winn, M. D., Ballard, C. C., Cowtan, K. D., Dodson, E. J., Emsley, P., Evans, P. R., Keegan, R. M., Krissinel, E. B., Leslie, A. G. W., McCoy, A., et al. (2011) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444910045749 · Cited by 12,353
PHENIX: a comprehensive Python-based system for macromolecular structure solution
Adams, P. D., Afonine, P. V., Bunkóczi, G., Chen, V. B., Davis, I. W., Echols, N., Headd, J. J., Hung, L.-W., Kapral, G. J., Grosse-Kunstleve, R. W., et al. (2012) · International Tables for Crystallography · doi:10.1107/97809553602060000865 · Cited by 7,334
The immune contexture in human tumours: impact on clinical outcome
Fridman, W. H., Pagès, F., Sautès-Fridman, C., & Galon, J. (2012) · Nature reviews. Cancer · doi:10.1038/nrc3245 · Cited by 4,981
Restoring function in exhausted CD8 T cells during chronic viral infection
Barber, D. L., Wherry, E. J., Masopust, D., Zhu, B., Allison, J. P., Sharpe, A. H., Freeman, G. J., & Ahmed, R. (2006) · Nature · doi:10.1038/nature04444 · Cited by 3,986
Multiple Sequence Alignment Using ClustalW and ClustalX
Thompson, J. D., Gibson, T. J., & Higgins, D. G. (2003) · Current Protocols in Bioinformatics · doi:10.1002/0471250953.bi0203s00 · Cited by 2,971 · cited 1×
“In addition, multiple sequencealignmentswereperformedusingClustalW 45 .”
iMOSFLM: a new graphical interface for diffraction-image processing with MOSFLM
Battye, T. G. G., Kontogiannis, L., Johnson, O., Powell, H. R., & Leslie, A. G. W. (2011) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444910048675 · Cited by 2,860 · cited 2×
“ThedatawereprocessedwithMosflm 40 andthe CCP 4softwaresuite 41 .”
Direct observation of individual endogenous protein complexes in situ by proximity ligation
Söderberg, O., Gullberg, M., Jarvius, M., Ridderstråle, K., Leuchowius, K.-J., Jarvius, J., Wester, K., Hydbring, P., Bahram, F., Larsson, L.-G., et al. (2006) · Nature Methods · doi:10.1038/nmeth947 · Cited by 2,419
Cited by
Items 101–200 of 718
Banerjee, H., & Kane, L. (2018) · F1000Research · doi:10.12688/f1000research.13446.1 · Cited by 98
Promising approaches in cancer immunotherapy
Taefehshokr, N., Baradaran, B., Baghbanzadeh, A., & Taefehshokr, S. (2019) · Immunobiology · doi:10.1016/j.imbio.2019.11.010 · Cited by 105
Targeting Tim-3 in Cancer With Resistance to PD-1/PD-L1 Blockade
Tian, T., & Li, Z. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.731175 · Cited by 104
“After BAT3 release, Src kinase binds and promotes the subsequent negative regulation of T-cell receptor (TCR) signal transduction (16, 17).”
BackgroundClayton, K., Douglas-Vail, M. B., Rahman, A. K. M. N.-U., Medcalf, K. E., Xie, I. Y., Chew, G. M., Tandon, R., Lanteri, M. C., Norris, P. J., Deeks, S. G., et al. (2015) · Journal of Virology · doi:10.1128/jvi.00006-15 · Cited by 102
“Coinhibitory molecules, including programmed death receptor 1 (PD-1) (2–6), lymphocyte activation gene-3 (LAG-3) (5, 7, 8), carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1) (9–12), and T cell immunoglobulin and mucin domain-containing protein 3 (Tim-3) (4, 12–14) contribute to T cell exhaustion, red…”
BackgroundInfluentialSelf-citationBeyond CTLA-4 and PD-1 Inhibition: Novel Immune Checkpoint Molecules for Melanoma Treatment
Ziogas, D. C., Theocharopoulos, C., Lialios, P., Foteinou, D., Koumprentziotis, I., Xynos, G., & Gogas, H. J. (2023) · Cancers · doi:10.3390/cancers15102718 · Cited by 99
“The main identified TIM-3 ligands include Galectin-9 [83], CEACAM1 [84], HMGB1 and phosphatidylserine [85], which bind to distinct regions of the extracellular Ig V domain.”
BackgroundKey Players of the Immunosuppressive Tumor Microenvironment and Emerging Therapeutic Strategies
Park, K., Veena, M. S., & Shin, D. S. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.830208 · Cited by 98
“T cell immunoglobulin andmucin-domain containing 3 (TIM3) promotes CD8 T cell apoptosis or exhaustion upon binding to its ligands, galectin-9 (gal-9), phosphatidylserine, high-mobility group protein B1, and carcinoembryonic antigen cell adhesion molecule 1 (Huang et al., 2015; Kang et al., 2015; Acharya et al., 2020).”
BackgroundThe bitter side of sweet: the role of Galectin-9 in immunopathogenesis of viral infections
Merani, S., Chen, W., & Elahi, S. (2015) · Reviews in Medical Virology · doi:10.1002/rmv.1832 · Cited by 99
“5 John Wiley & Sons, Ltd. by virtually all immune cells, either constitutively or in an inducible manner, and are significantly upregulated by B cells, Tcells, natural killer (NK) cells, inflammatory macrophages, and regulatory T cells (Tregs) upon activation [2].”
BackgroundInfluentialTIM-3 pathway dysregulation and targeting in cancer
Zeidan, A. M., Komrokji, R. S., & Brunner, A. M. (2021) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2021.1865814 · Cited by 97
“CEACAM1 is also thought to bind TIM-3 in the pocket created from the FG and CC′ loops [38].”
BackgroundTumor Immunology and Immunotherapy of Non-Small-Cell Lung Cancer
Cascone, T., Fradette, J. J., Pradhan, M., & Gibbons, D. L. (2021) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a037895 · Cited by 100
The gut microbiota mediates protective immunity against tuberculosis via modulation of lncRNA
Yang, F., Yang, Y., Chen, L., Zhang, Z., Liu, L., Zhang, C., Mai, Q., Chen, Y., Chen, Z., Lin, T., et al. (2022) · Gut Microbes · doi:10.1080/19490976.2022.2029997 · Cited by 92
Immune checkpoint TIM-3 regulates microglia and Alzheimer’s disease
Kimura, K., Subramanian, A., Yin, Z., Khalilnezhad, A., Wu, Y., He, D., Dixon, K. O., Chitta, U. K., Ding, X., Adhikari, N., et al. (2025) · Nature · doi:10.1038/s41586-025-08852-z · Cited by 85
Self-citationRegulatory Mechanisms of Inhibitory Immune Checkpoint Receptors Expression
Curdy, N., Lanvin, O., Laurent, C., Fournié, J.-J., & Franchini, D.-M. (2019) · Trends in Cell Biology · doi:10.1016/j.tcb.2019.07.002 · Cited by 83
T‐cell immunoglobulin mucin 3 blockade drives an antitumor immune response in head and neck cancer
Liu, J., Ma, S., Mao, L., Bu, L., Yu, G., Li, Y., Huang, C., Deng, W., Kulkarni, A. B., Zhang, W., et al. (2017) · Molecular Oncology · doi:10.1002/1878-0261.12029 · Cited by 88
“A recent research also demonstrated that interactions between CEACAM1 and TIM3 determine the function of TIM3 (Huang et al., 2015).”
BackgroundTumor cell-intrinsic Tim-3 promotes liver cancer via NF-κB/IL-6/STAT3 axis
Zhang, H., Song, Y., Yang, H., Liu, Z., Gao, L., Liang, X., & Ma, C. (2018) · Oncogene · doi:10.1038/s41388-018-0140-4 · Cited by 90
Tr1-Like T Cells – An Enigmatic Regulatory T Cell Lineage
White, A. M., & Wraith, D. C. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00355 · Cited by 93
“Furthermore, lower proportions of tumor-infiltrating murine CD4+ and CD8+ T cells produced IL-10 after co-blockade of CEACAM-1 and TIM-3 in vivo (50).”
BackgroundResultInfluentialBeyond T cell exhaustion: TIM-3 regulation of myeloid cells
Dixon, K. O., Lahore, G. F., & Kuchroo, V. K. (2024) · Science Immunology · doi:10.1126/sciimmunol.adf2223 · Cited by 93
“…that include galectin-9 (GAL-9) ( 43 ), phosphatidyl-serine ( 44 ), high-mobility group protein B1 (HMGB1) ( 45 ), and carcinoembryonic antigen cell adhesion molecule 1 (CEACAM-1) ( 46 ), which are expressed on the surface of damaged cells, cancer cells, and antigen-presenting cells (APCs) (Fig.”
BackgroundSelf-citationControl of NK Cell Activation by Immune Checkpoint Molecules
Beldi‐Ferchiou, A., & Caillat‐Zucman, S. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18102129 · Cited by 86
“In addition to galectin-9 [81], Tim-3 has been reported to bind other ligands such as phosphatidylserine exposed by apoptotic cells [83], the alarmin HMGB1 [84], and the carcinoembryonic antigen cell adhesion molecule 1 (CEACAM1) [85].”
BackgroundLi, H., Yang, Z., & Guo, Q. (2021) · Cell Communication and Signaling · doi:10.1186/s12964-021-00789-w · Cited by 95
“Its ligands include protein ligands such as galectin-9 [79], carcinoembryonic antigen cell adhesion molecule 1 [80], high mobility group box 1 [81] and non-protein ligand phosphatidylserine [82].”
BackgroundKreidieh, F., & Tawbi, H. A. (2023) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359231186027 · Cited by 95
News on immune checkpoint inhibitors as immunotherapy strategies in adult and pediatric solid tumors
Melaiu, O., Lucarini, V., Giovannoni, R., Fruci, D., & Gemignani, F. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.07.001 · Cited by 79
Emerging Trends in Immunotherapy for Cancer
Mishra, A. K., Ali, A., Dutta, S., Banday, S., & Malonia, S. K. (2022) · Diseases · doi:10.3390/diseases10030060 · Cited by 88
Dong, Y., Tang, X., Zhang, Z., Song, J., Niu, T., Shan, D., & Zeng, H. (2020) · Matter · doi:10.1016/j.matt.2020.05.004 · Cited by 77
Co-expression of TIM-3 and CEACAM1 promotes T cell exhaustion in colorectal cancer patients
Zhang, Y., Cai, P., Li, L., Shi, L., Chang, P., Liang, T., Yang, Q., Liu, Y., Wang, L., & Hu, L. (2016) · International Immunopharmacology · doi:10.1016/j.intimp.2016.12.024 · Cited by 79
Neutrophil Extracellular Traps in Cancer Therapy Resistance
Shahzad, M. H., Feng, L., Su, X., Brassard, A., Dhoparee‐Doomah, I., Ferri, L. E., Spicer, J. D., & Cools‐Lartigue, J. (2022) · Cancers · doi:10.3390/cancers14051359 · Cited by 81
Emerging Immunotherapy for Acute Myeloid Leukemia
Tabata, R., Chi, S., Yuda, J., & Minami, Y. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22041944 · Cited by 83
“TIM-3 is also able to bind phosphatidylserine (PtdSer) [30], HMGB1 [31], and CEACAM1 [32] to prevent the activation of the immune response.”
BackgroundInhibitory Receptors and Immune Checkpoints Regulating Natural Killer Cell Responses to Cancer
Buckle, I., & Guillerey, C. (2021) · Cancers · doi:10.3390/cancers13174263 · Cited by 79
“TIM-3 T, NK, NKT cells and myeloid cells Galectin-9 (Gal-9) Phosphatidylserine (PtdSer); High mobility group protein B1- HMGB1; Carcinoembryonic antigen cell adhesion molecule 1 CEACAM-1 [156,157]”
BackgroundTim-3 mediates T cell trogocytosis to limit antitumor immunity
Pagliano, O., Morrison, R. M., Chauvin, J.-M., Banerjee, H., Davar, D., Ding, Q., Tanegashima, T., Gao, W., Chakka, S. R., Deblasio, R. N., et al. (2022) · Journal of Clinical Investigation · doi:10.1172/jci152864 · Cited by 78
Self-citationEarly stage gastric adenocarcinoma: clinical and molecular landscapes
Hirata, Y., Noorani, A., Song, S., Wang, L., & Ajani, J. A. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00767-w · Cited by 89
Reprogramming the tumor microenvironment to enhance adoptive cellular therapy
Beavis, P. A., Slaney, C. Y., Kershaw, M. H., Gyorki, D. E., Neeson, P. J., & Darcy, P. K. (2015) · Seminars in Immunology · doi:10.1016/j.smim.2015.11.003 · Cited by 80
Modulation of innate immunity in the tumor microenvironment
González-Gugel, E., Saxena, M., & Bhardwaj, N. (2016) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-016-1859-9 · Cited by 73
Beyond PD-1/PD-L1 Inhibition: What the Future Holds for Breast Cancer Immunotherapy
Chrétien, S., Zerdes, I., Bergh, J. C. S., Matikas, A., & Foukakis, T. (2019) · Cancers · doi:10.3390/cancers11050628 · Cited by 78
Significance of TIM3 expression in cancer: From biology to the clinic
Solinas, C., Silva, P. D., Bron, D., Willard-Gallo, K. E., & Sangiolo, D. (2019) · Seminars in Oncology · doi:10.1053/j.seminoncol.2019.08.005 · Cited by 78
Cutting-Edge: Preclinical and Clinical Development of the First Approved Lag-3 Inhibitor
Chocarro, L., Bocanegra, A., Blanco, E., Fernández, L., Arasanz, H., Echaide, M., Garnica, M., Ramos, P., Piñeiro‐Hermida, S., Vera, R., et al. (2022) · Cells · doi:10.3390/cells11152351 · Cited by 77
“Its known ligands are galectin-9 [135], CEACAM-1 [136], phosphatidylserine [137], and HMGB1 [138], which interact with different regions of the TIM-3 extracellular immunoglobulin V domain, leading to the activation of differential signaling cascades.”
BackgroundGestermann, N., Saugy, D., Martignier, C., Tillé, L., Fuertes Marraco, S. A., Zettl, M., Tirapu, I., Speiser, D. E., & Verdeil, G. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1736792 · Cited by 69
“One possible explanation for these contradictory reports is related to the expression of CEACAM-1, which would regulate the inhibitory function of TIM-3 in T cells.(38) In our settings, T cells co-expressed both TIM-3 and CEACAM-1 (not shown).”
BackgroundTIM-3 in Leukemia; Immune Response and Beyond
Rezaei, M., Tan, J., Zeng, C., Li, Y., & Ganjalıkhani-Hakemi, M. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.753677 · Cited by 73
“The last ligand is carcinoembryonic antigen cell adhesion molecule 1 (CEACAM-1), which can have both cis and trans interactions with TIM-3 (20).”
BackgroundImmune checkpoint blockade in HIV
Gubser, C., Chiu, C. Y. H., Lewin, S. R., & Rasmussen, T. A. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2022.103840 · Cited by 80
Neural immunoglobulin superfamily interaction networks
Zinn, K., & Özkan, E. (2017) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2017.05.010 · Cited by 72
NK Cell-Based Immunotherapy for Hematological Malignancies
Sivori, S., Meazza, R., Quintarelli, C., Carlomagno, S., Chiesa, M. D., Falco, M., Moretta, L., Locatelli, F., & Pende, D. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8101702 · Cited by 69
CAR T cell-based immunotherapy and radiation therapy: potential, promises and risks
Hovhannisyan, L., Riether, C., Aebersold, D. M., Medová, M., & Zimmer, Y. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01775-1 · Cited by 74
Co-Signaling Molecules in Maternal–Fetal Immunity
Xu, Y., Wang, S., Li, D., & Du, M. (2016) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2016.11.001 · Cited by 71
“First trimester Third trimester Syncy otrophoblasts: PD-L1, CD200, CD200R1 PD-L2 Cytotrophoblasts: PD-L1, CD200, CD200R1 EVTs: ICOS-L, PD-L1, B7-H3, CEACAM1 Gal-9, CD200, CD200R1, CD155, CD112 Expression undefined DSCs: TIM-3, Gal-9”
BackgroundInfluentialMonoclonal Antibodies for the Treatment of Melanoma: Present and Future Strategies
Bhandaru, M., & Rotte, A. (2018) · Methods in molecular biology · doi:10.1007/978-1-4939-8958-4_4 · Cited by 70
Current Progress and Future Perspectives of Immune Checkpoint in Cancer and Infectious Diseases
Cai, X., Zhan, H., Ye, Y., Yang, J., Zhang, M., Li, J., & Zhuang, Y. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2021.785153 · Cited by 66
“CEACAM-1 coexpressed with TIM-3 is considered to be required for the regulatory function of TIM-3 (Huang et al., 2015).”
BackgroundLi, X., Wang, R., Fan, P., Yao, X., Qin, L., Peng, Y., Ma, M., Asley, N., Chang, X., Feng, Y., et al. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01066 · Cited by 74
Morimoto, T., Nakazawa, T., Matsuda, R., Nishimura, F., Nakamura, M., Yamada, S., Nakagawa, I., Park, Y.-S., Tsujimura, T., & Nakase, H. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22073489 · Cited by 72
“Expression of the TIM3 ligands, Galectin 9, Phosphatidylserine, HMGB1 and CEACAM1 in gliomas in TCGA data set.”
BackgroundInfluentialPromising immunotherapy targets: TIM3, LAG3, and TIGIT joined the party
Lu, C., & Tan, Y. (2024) · Molecular Therapy Oncology · doi:10.1016/j.omton.2024.200773 · Cited by 89
Carcinoembryonic antigen (CEACAM) family members and Inflammatory Bowel Disease
Kelleher, M., Singh, R., O’Driscoll, C. M., & Melgar, S. (2019) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2019.05.008 · Cited by 75
Immunotherapy for Colorectal Cancer: Mechanisms and Predictive Biomarkers
Carlsen, L., Huntington, K. E., & El‐Deiry, W. S. (2022) · Cancers · doi:10.3390/cancers14041028 · Cited by 74
“Co-inhibition of TIM-3 and CEACAM1 results in improved elimination of CRC tumors in mice [74]; however, no clinical trials are currently investigating this combination for CRC.”
BackgroundAn optimal portfolio of photothermal combined immunotherapy
Zeng, W., Li, Z., Chen, H., Zeng, X., & Mei, L. (2022) · Cell Reports Physical Science · doi:10.1016/j.xcrp.2022.100898 · Cited by 72
Yin, N., Li, X., Zhang, X., Xue, S., Cao, Y., Niedermann, G., Lu, Y., & Xue, J. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01826-z · Cited by 79
Role of immune system in tumor progression and carcinogenesis
Upadhyay, S., Sharma, N., Gupta, K. B., & Dhiman, M. (2018) · Journal of Cellular Biochemistry · doi:10.1002/jcb.26663 · Cited by 69
“Another novel approach is through targeting the CEACAM1/TIM-3 interaction as a Treg exhaustion mechanism in immuno-oncotherapy.(127) The future antitumor era will be based on different combinatorial trials and synergistic action of drugs.”
BackgroundGu, S., Zaidi, S., Hassan, M. I., Mohammad, T., Malta, T. M., Noushmehr, H., Nguyen, B., Crandall, K. A., Srivastav, J., Obias, V., et al. (2020) · Gastroenterology · doi:10.1053/j.gastro.2019.09.023 · Cited by 63
Current State of Melanoma Therapy and Next Steps: Battling Therapeutic Resistance
Fateeva, A., Eddy, K., & Chen, S. (2024) · Cancers · doi:10.3390/cancers16081571 · Cited by 77
“Carcinoembryonic antigen cell adhesion molecule-1 (CEACAM1) is another target in IFN-γ signaling that heterodimerizes with TIM-3 and promotes T-cell exhaustion to suppress the immune system [281].”
BackgroundMa, S., Tian, Y., Peng, J., Chen, C., Peng, X., Zhao, F., Li, Z., Li, M., Zhao, F., Sheng, X., et al. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.adg6752 · Cited by 68
“It has been reported that PtdSer and CEACAM1 bind with Tim-3 at the same pocket, whereas galectin-9 interacts with the opposite site of the FG-CC 0 loop ( 15 , 16 ).”
BackgroundTargeting B7‐1 in immunotherapy
Chen, R., Ganesan, A., Okoye, I., Arutyunova, E. I., Elahi, S., Lemieux, M. J., & Barakat, K. (2019) · Medicinal Research Reviews · doi:10.1002/med.21632 · Cited by 67
KIM-1/TIM-1 is a Receptor for SARS-CoV-2 in Lung and KidneyPreprint
Mori, Y., Fink, C., Ichimura, T., Sako, K., Mori, M., Lee, N. N., Aschauer, P., Das, K. M., Hong, S., Song, M., et al. (2020) · medRxiv · doi:10.1101/2020.09.16.20190694 · Cited by 64
Khosravi, N., Mokhtarzadeh, A., Baghbanzadeh, A., Hajiasgharzadeh, K., Khaze, V., Hemmat, N., Safarzadeh, E., & Baradaran, B. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.118005 · Cited by 66
Immune checkpoint inhibitors for cancer treatment
Park, J., Kwon, M., & Shin, E. (2016) · Archives of Pharmacal Research · doi:10.1007/s12272-016-0850-5 · Cited by 63
CEACAM1 in Liver Injury, Metabolic and Immune Regulation
Horst, A. K., Najjar, S. M., Wagener, C., & Tiegs, G. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19103110 · Cited by 65
“It associates with CEACAM1 via its extracellular domains as a heterodimer in both Cis and Trans, and this interaction is required to enhance TIM-3 cell surface expression and maturation, as well as promoting its inhibitory functions [187,188].”
BackgroundSandu, I., Cerletti, D., Claassen, M., & Oxenius, A. (2020) · Nature Communications · doi:10.1038/s41467-020-18256-4 · Cited by 69
A TIM-3 Oligonucleotide Aptamer Enhances T Cell Functions and Potentiates Tumor Immunity in Mice
Gefen, T., Castro, I., Muharemagic, D., Puplampu-Dove, Y., Patel, S., & Gilboa, E. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.06.023 · Cited by 63
“Gal-9 is a soluble molecule that is widely expressed in many cells, and its expression is further upregulated by IFN-g.11,12 Gal-9 binding to TIM-3 expressed on Th1 CD4+ T cells was shown to induce cell death, and blockade of the TIM-3-Gal-9 interaction with TIM-3 or Gal-9 antibodies reduced cell death.13,14 To determ…”
BackgroundThe Therapeutic Potential of Regulatory T Cells: Challenges and Opportunities
Bayati, F., Mohammadi, M., Valadi, M., Jamshidi, S., Foma, A. M., & Sharif‐Paghaleh, E. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.585819 · Cited by 67
Immune checkpoint blockade in pancreatic cancer: Trudging through the immune desert
Li, X., Gulati, M., Larson, A. C., Solheim, J. C., Jain, M., Kumar, S., & Batra, S. K. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.08.009 · Cited by 58
NETosis as an oncologic therapeutic target: a mini review
Jaboury, S., Wang, K., O’Sullivan, K. M., Ooi, J. D., & Ho, G. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1170603 · Cited by 68
“Agonist of trained immunity Enhance N1 anticancer activity Beta glucan In vivo murine model of melanoma (61)”
BackgroundHepatic CEACAM1 expression indicates donor liver quality and prevents early transplantation injury
Nakamura, K., Kageyama, S., Kaldas, F. M., Hirao, H., Ito, T., Kadono, K., Dery, K. J., Kojima, H., Gjertson, D. W., Sosa, R. A., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci133142 · Cited by 59
“As proficient CEACAM1 – TIM-3 signaling pathway is required to mediate T-cell exhaustion in autoimmunity and anti-tumor immunity (39), we currently analyze whether CEACAM1 – TIM-3 crosstalk on host circulating CD4+ T cells might promote exhaustion-type phenotype in IR-stressed”
BackgroundRabal, O., Pastor, F., Villanueva, H., Soldevilla, M. M., Hervás‐Stubbs, S., & Oyarzábal, J. (2016) · Molecular Therapy — Nucleic Acids · doi:10.1038/mtna.2016.84 · Cited by 58
NK cell expression of Tim-3: First impressions matter
So, E. C., Khaladj-Ghom, A., Ji, Y., Amin, J., Song, Y., Burch, E. E., Zhou, H., Sun, H., Chen, S., Bentzen, S. M., et al. (2019) · Immunobiology · doi:10.1016/j.imbio.2019.03.001 · Cited by 60
Next generation of immune checkpoint molecules in maternal‐fetal immunity*
Zhao, S., Muyayalo, K. P., Luo, J., Huang, D., Mor, G., & Liao, A. (2022) · Immunological Reviews · doi:10.1111/imr.13073 · Cited by 58
Immune checkpoint inhibitors associated cardiovascular immune-related adverse events
Jo, W., Won, T., Daoud, A., & Čiháková, D. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1340373 · Cited by 55
Patsoukis, N., Weaver, J. D., Strauss, L., Herbel, C., Seth, P., & Boussiotis, V. A. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00330 · Cited by 60
“Y256 and Y263 can be phosphorylated by Src kinases (149) or ITK (150) and are involved in the binding of Bat3 (HLA-B associated transcript 3), p85 PI3K, Fyn, and/or Lck (149, 151).”
BackgroundInfluentialEnhanced expression of immune checkpoint receptors during SARS-CoV-2 viral infection
Sharif‐Askari, N. S., Sharif‐Askari, F. S., Mdkhana, B., Heialy, S. A., AlSafar, H. S., Hamoudi, R., Hamid, Q. A., & Halwani, R. (2020) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2020.11.002 · Cited by 60
Leo, I. R., Aswad, L., Stahl, M. M. S., Kunold, E., Post, F., Erkers, T., Struyf, N., Mermelekas, G., Joshi, R. N., Villacampa, E. G., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-29224-5 · Cited by 62
“Additionally, B-CLC5 was characterized by the abundance of the adhesion molecule CEACAM1, which induces a tolerogenic immune environment through interactions with TIM3 47 , suggesting a common retained af fi nity for oncogenic immunomodulation 48 .”
Tim-3 and Tim-4 as the potential targets for antitumor therapy
Cheng, L., & Ruan, Z. (2015) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2015.1056953 · Cited by 54
“20 Also, co-blockade of CEACAM1 and TIM-3 leads to enhancement of anti-tumor immune responses with improved elimination of tumors in mouse colorectal cancer models.(6) Other negative checkpoint regulators expression on tumor-infiltrating lymphocytes, such as cytotoxic T lymphocyte antigen-4 (CTLA-4), lymphocyte activa…”
BackgroundNew advances in immunotherapy for non-small cell lung cancer.
Qin, H., Wang, F., Liu, H., Zeng, Z., Wang, S., Pan, X. H., & Gao, H. (2018) · Europe PMC (PubMed Central) · Cited by 53
Wuerdemann, N., Pütz, K., Eckel, H. N. C., Jain, R. A., Wittekindt, C., Huebbers, C. U., Sharma, S. J., Langer, C., Gattenlöhner, S., Büttner, R., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms22010379 · Cited by 61
Combinatorial blockade for cancer immunotherapy: targeting emerging immune checkpoint receptors
Roy, D., Gilmour, C., Patnaik, S., & Wang, L. L. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1264327 · Cited by 53
Gandhi, A. K., Kim, W. M., Sun, Z.-Y. J., Huang, Y.-H., Bonsor, D. A., Sundberg, E. J., Kondo, Y., Wagner, G., Kuchroo, V. K., Petsko, G., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-35754-0 · Cited by 51
Self-citationOne Stone, Two Birds: The Roles of Tim-3 in Acute Myeloid Leukemia
Wang, Z., Chen, J., Wang, M., Zhang, L., & Yu, L. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.618710 · Cited by 60
“Therefore, the Tim-3/ CEACAM1 interaction in the tumor microenvironment is very complex and further exploration of the underlying molecular mechanisms is needed to elucidate the regulatory mechanism (31).”
BackgroundImmune checkpoints and cancer development: Therapeutic implications and future directions
Mehdizadeh, S., Bayatipoor, H., Pashangzadeh, S., Jafarpour, R., Shojaei, Z., & Motallebnezhad, M. (2021) · Pathology - Research and Practice · doi:10.1016/j.prp.2021.153485 · Cited by 56
Regulation of activated T cell survival in rheumatic autoimmune diseases
Rosetti, F., Madera-Salcedo, I. K., Rodríguez‐Rodríguez, N., & Crispín, J. C. (2022) · Nature Reviews Rheumatology · doi:10.1038/s41584-021-00741-9 · Cited by 63
Kataoka, S., Manandhar, P., Lee, J., Workman, C. J., Banerjee, H., Szymczak-Workman, A. L., Kvorjak, M., Lohmueller, J. J., & Kane, L. (2021) · Science Signaling · doi:10.1126/scisignal.aba0717 · Cited by 54
“Whereas several ligands for Tim-3 have been described (8, 53), including galectin-9, HMGB1, PS, and CEACAM1, none of these is exclusive to Tim-3.”
BackgroundInfluentialInhibitory pattern recognition receptors
Rumpret, M., von Richthofen, H. J., Peperzak, V., & Meyaard, L. (2021) · The Journal of Experimental Medicine · doi:10.1084/jem.20211463 · Cited by 52
Yuan, S., Cao, L., Ling, H., Dang, M., Sun, Y., Zhang, X., Chen, Y., Zhang, L., Su, D., Wang, X., et al. (2015) · Protein & Cell · doi:10.1007/s13238-015-0220-y · Cited by 51
Exploiting NK Cell Surveillance Pathways for Cancer Therapy
Barrow, A. D., & Colonna, M. (2019) · Cancers · doi:10.3390/cancers11010055 · Cited by 55
“However, other groups could find no evidence of an interaction between human or mouse Tim-3 and galactin-9 [74] and the crystal structure of a heterodimer between the V domains of CEACAM-1 and Tim-3 has since been withdrawn [69].”
BackgroundSchwartz, S., Patel, N., Longmire, T. A., Jayaraman, P., Jiang, X., Lu, H., Baker, L. M., Velez, J., Ramesh, R., Wavreille, A., et al. (2022) · Immunotherapy Advances · doi:10.1093/immadv/ltac019 · Cited by 58
CEACAMS 1, 5, and 6 in disease and cancer: interactions with pathogens
Thomas, J., Klebanov, A., John, S., Miller, L. S., Vegesna, A. K., AMDUR, R. L., Bhowmick, K., & Mishra, L. (2023) · Genes & Cancer · doi:10.18632/genesandcancer.230 · Cited by 58
“Knockout of CEACAM1 leads to the development of exhaustion-resistant and hyperinflammatory T cells, a phenotype mediated by CEACAM1-TIM-3 interactions [36].”
BackgroundMethodInfluentialImmune checkpoint molecules in acute myeloid leukaemia: managing the double‐edged sword
Hobo, W. A., Hutten, T. J. A., Schaap, N. P., & Dolstra, H. (2018) · British Journal of Haematology · doi:10.1111/bjh.15078 · Cited by 58
Adaptive NKG2C+CD57+ Natural Killer Cell and Tim-3 Expression During Viral Infections
Kared, H., Martelli, S., Tan, S. W., Simoni, Y., Chong, M. L., Yap, S. H., Newell, E. W., Pender, S. L. F., Kamarulzaman, A., Rajasuriar, R., et al. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00686 · Cited by 55
“Since our understanding of the role of Tim-3 in NK cells is at its infancy, we made inferences from observations with T cells, where Ceacam-1 was recently identified as an important inhibitory ligand (26).”
BackgroundResultInfluentialCEACAM1 promotes CD8+ T cell responses and improves control of a chronic viral infection
Khairnar, V., Duhan, V., Patil, A., Zhou, F., Bhat, H., Thöns, C., Sharma, P., Adomati, T., Friendrich, S.-K., Bezgovsek, J., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-04832-2 · Cited by 55
Immune Checkpoints in Cancers: From Signaling to the Clinic
Pisibon, C., Ouertani, A., Bertolotto, C., Ballotti, R., & Chéli, Y. (2021) · Cancers · doi:10.3390/cancers13184573 · Cited by 58
“As a matter of fact, it has been suggested that TIM-3 inhibitory function is dependent on the co-expression of ceacam-1 in tumors and autoimmune diseases [89].”
BackgroundSchafer, J. L., Li, H., Evans, T. I., Estes, J. D., & Reeves, R. K. (2015) · Journal of Virology · doi:10.1128/jvi.00660-15 · Cited by 49
“Interestingly, Tim-3 blockade has already been shown to reverse NK cell exhaustion and promote tumor lysis in anticancer studies (37, 38).”
BackgroundIdentification of TIM3 2′-fluoro oligonucleotide aptamer by HT-SELEX for cancer immunotherapy
Hervas-Stubbs, S., Soldevilla, M. M., Villanueva, H., Mancheño, U., Bendandi, M., & Pastor, F. (2016) · Oncotarget · doi:10.18632/oncotarget.6608 · Cited by 49
“However, there are some recent publications indicating that there might be other ligands that still need to be identified [14].”
BackgroundPhenotypic and functional analysis of malignant mesothelioma tumor-infiltrating lymphocytes
Klampatsa, A., O’Brien, S., Thompson, J. C., Rao, A. S., Stadanlick, J. E., Martinez, M. C., Liousia, M., Cantu, E., Cengel, K. A., Moon, E. K., et al. (2019) · OncoImmunology · doi:10.1080/2162402x.2019.1638211 · Cited by 54
Masciale, V., Grisendi, G., Banchelli, F., D’Amico, R., Maiorana, A., Sighinolfi, P., Stefani, A., Morandi, U., Dominici, M., & Aramini, B. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01394 · Cited by 48
“Indeed, similar to targeted therapy, patients may eventually develop resistance to immunotherapy (25, 26), and some may even suffer hyperprogression after immunotherapy (27, 28).”
BackgroundLiao, Y., Li, H., Cao, H., Dong, Y., Gao, L., Liu, Z., Ge, J., & Zhu, H. (2020) · Protein & Cell · doi:10.1007/s13238-020-00750-6 · Cited by 48
The Role of TIM-3 in Hepatocellular Carcinoma: A Promising Target for Immunotherapy?
Ganjalıkhani-Hakemi, M., Jafarinia, M., Azizi, M., Rezaeepoor, M., Isayev, O., & Bazhin, A. V. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.601661 · Cited by 58
“The stability of mature TIM-3 on the cell surface is promoted via cis interaction, and both cis and trans interactions mediate the inhibitory function of TIM-3 (16, 22).”
BackgroundThe New Era of Cancer Immunotherapy
Khalil, D. N., Budhu, S., Gasmi, B., Zappasodi, R., Hirschhorn-Cymerman, D., Plitt, T., Henau, O. D., Zamarin, D., Holmgaard, R., Murphy, J. T., et al. (2015) · Advances in cancer research · doi:10.1016/bs.acr.2015.04.010 · Cited by 51
Role of Tim-3 in hepatitis B virus infection: An overview
Liu, Y., Gao, L., Liang, X., & Ma, C. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i7.2294 · Cited by 47
Association of TIM-3 expression with glucose metabolism in Jurkat T cells
Lee, M. J., Yun, S. J., Lee, B., Jeong, E., Yoon, G., Kim, K. H., & Park, S. (2020) · BMC Immunology · doi:10.1186/s12865-020-00377-6 · Cited by 51
Tim-3 as a diagnostic and prognostic biomarker of osteosarcoma
Ge, W., Li, J., Fan, W., Xu, D., & Sun, S. (2017) · Tumor Biology · doi:10.1177/1010428317715643 · Cited by 45
Switch receptor T3/28 improves long-term persistence and antitumor efficacy of CAR-T cells
Zhao, S., Wang, C., Lu, P., Lou, Y., Liu, H., Wang, T., Yang, S., Bao, Z., Han, L. G., Liang, X., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003176 · Cited by 52
Metadata
- Authors
- Huang, Y.-H., Zhu, C., Kondo, Y., Anderson, A. C., Gandhi, A., Russell, A., Dougan, S. K., Petersen, B.-S., Melum, E., Pertel, T., Clayton, K. L., Raab, M., Chen, Q., Beauchemin, N., Yazaki, P. J., Pyzik, M., Ostrowski, M. A., Glickman, J. N., Rudd, C. E., Ploegh, H. L., Franke, A., Petsko, G. A., Kuchroo, V. K., & Blumberg, R. S.
- Affiliations
- Brigham and Women's Hospital (US)
- Brandeis University (US)
- Massachusetts Institute of Technology (US)
- Christian-Albrechts-Universität zu Kiel (DE)
- Oslo University Hospital (NO)
- University of Toronto (CA)
- University of Cambridge (GB)
- Sichuan University (CN)
- McGill University (CA)
- City Of Hope National Medical Center (US)
- St. Michael's Hospital (CA)
- Corresponding author
- Blumberg, Richard S.
- ORCID
- Venue
- Nature
- Published
- 2014-10-26
- Volume
- 517
- Issue
- 7534
- Pages
- 386-390
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC4297519
- OpenAlex
- W2122730216
- Cited by
- 717
- References
- 58
- Citations by year
- 2026: 44 · 2025: 72 · 2024: 85 · 2023: 82 · 2022: 71 · 2021: 82 · 2020: 76 · 2019: 51 · 2018: 47 · 2017: 40 · 2016: 38 · 2015: 28
- FWCI
- 17.07
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health (UL1TR001102)
- National Institute of General Medical Sciences (R01GM032415, T32GM007122, GM-32415, R37GM032415, P41GM111244, R01GM026788)
- National Institute of Allergy and Infectious Diseases (AI 056299, P01AI073748, AI039671, AI073748, P01AI056299, P01AI039671)
- National Institute of Diabetes and Digestive and Kidney Diseases (DK044319, DK0034854, R01DK053056, DK088199, DK053056, R56DK053056, DK051362, R37DK044319, R01DK051362, P30DK034854, R01DK044319, R01DK088199)
- National Institute of Neurological Disorders and Stroke (NS045937, R01NS045937)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- TIM-3, T cell exhaustion, immune tolerance, immune checkpoint, T cell co-inhibition, T cell costimulation, colorectal cancer, antitumor immunity, T cell receptor signaling
- MeSH terms
- Hepatitis A Virus Cellular Receptor 2, Animals, Cell Line, Disease Models, Animal, Female, Humans, Immune Tolerance, Inflammation, Ligands, Male, Membrane Proteins, Mice, Inbred BALB C, Mice, Inbred C57BL, Models, Molecular, Mucous Membrane, Protein Conformation, Receptors, Virus, T-Lymphocytes, Colorectal Neoplasms, Autoimmunity, Antigens, CD, Cell Adhesion Molecules, Mice, Protein Multimerization
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.